Assessment of Alteration of Serum Adiponectin Levels in Migraineurs: An Interventional Case Control Study

Abstract

Background and Objectives: Migraine is one of the major headache disorders. Epidemiological studies have shown its high prevalence and negative impact on personal and socioeconomic aspects. It is currently ranked 19th by the “World Health Organization” amongst all diseases, leading to disability worldwide. Inflammatory mediators, which include adipokines, have been analyzed in migraine pathophysiology. Nevertheless, their role is not well recognized. This study is aimed to assess serum high molecular weight adiponectin (HMW-ADP) levels in migraineurs: during the ictal phase, prior to, and postabortive treatment. Methods: This was a hospital-based interventional case-controlled study, checking the peripheral blood samples from migraineurs during an acute attack and after one hour of treatment with naproxen sodium (10–15 mg/kg). Age, sex, and BMI matched controls without headache were taken, and a single blood sample was drawn in them. HMW-ADP levels were evaluated by immunoassays. Results: A total of 120 patients which included 60 migraine patients along with 60 controls without headache were involved in the study. HMW-ADP was higher in migraine patients (9.89 ± 5.04 mcg/mL) than in patients without headache history (4.63 ± 2.98 mcg/mL; P = < .001); along with this, serum HMW-ADP (6.4 ± 4.09 mcg/mL; P = <.001) was found to be significantly lower in responders 60 min after acute abortive treatment. Conclusion: HMW-ADP levels were raised in migraineurs. Additionally, among responders following abortive treatment a considerable reduction in the levels was noted. These results recommend that the HMW-ADP might be a possible “novel biomarker of acute remedy response in acute migraineurs”.

Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics

“…Obesity has been shown to be a risk factor for the development of migraine ( Santos et al, 2015 ; Gelaye et al, 2017 ; Miri et al, 2018 ) and it is hypothesized that increased levels of inflammatory mediators, increased sympathetic activity, and increased leptin ( Pisanu et al, 2017 ) which are associated with obesity might influence the development of migraine. Adiponectin is also suspected to play a role ( Duarte et al, 2014 ; Abbasi et al, 2019 ; Joshi et al, 2020 ) although there are contrasting opinions on this ( Dearborn et al, 2014 ; Peterlin et al, 2016 ). Depression is another risk factor for migraine development ( Breslau et al, 2003 ; Karakurum et al, 2004 ) as well as episodic to chronic migraine progression.…”